Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment

NCT06411210 on ClinicalTrials.gov · last registry update 2026-08-04

A small phase 2 — 54 participants, against a typical 110. Due to report 30 April 2028, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Change in VAT/(VAT+SAT) from baseline to 12 months. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 16 July 2024 — 2 years so far. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: RECRUITING
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Yale University
Sponsor type: Other
Enrollment: 54
Started: 2024-07-16
Primary completion: 2028-04-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in VAT/(VAT+SAT) from baseline to 12 months

Conditions studied

Diabetes type1 · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.